Journal of Liver Cancer最新文献

Transarterial chemoembolization for hepatocellular carcinoma: 2023 expert consensus-based practical recommendations of the Korean Liver Cancer Association. 肝细胞癌的动脉化疗栓塞：2023年韩国癌症协会基于专家共识的实用建议。

Journal of Liver Cancer Pub Date : 2023-09-01 Epub Date: 2023-07-14 DOI: 10.17998/jlc.2023.05.22

Yuri Cho, Jin Woo Choi, Hoon Kwon, Kun Yung Kim, Byung Chan Lee, Hee Ho Chu, Dong Hyeon Lee, Han Ah Lee, Gyoung Min Kim, Jung Suk Oh, Dongho Hyun, In Joon Lee, Hyunchul Rhim

{"title":"Transarterial chemoembolization for hepatocellular carcinoma: 2023 expert consensus-based practical recommendations of the Korean Liver Cancer Association.","authors":"Yuri Cho, Jin Woo Choi, Hoon Kwon, Kun Yung Kim, Byung Chan Lee, Hee Ho Chu, Dong Hyeon Lee, Han Ah Lee, Gyoung Min Kim, Jung Suk Oh, Dongho Hyun, In Joon Lee, Hyunchul Rhim","doi":"10.17998/jlc.2023.05.22","DOIUrl":"10.17998/jlc.2023.05.22","url":null,"abstract":"Transarterial chemoembolization (TACE) was introduced in 1977 with the administration of chemotherapeutic agent to gelatin sponge particles through the hepatic artery in patients with hepatocellular carcinoma (HCC) and was established as conventional TACE using Lipiodol in the 1980s. In the 2000s, drug-eluting beads were developed and applied clinically. Currently, TACE is a commonly used non-surgical treatment modality for patients with HCC who are unsuitable for curative treatment. Considering the vital role of TACE in the management of HCC, it is crucial to organize current knowledge and expert opinions regarding patient preparation, procedural techniques, and post-treatment care in TACE, which can enhance therapeutic efficacy and safety. A group of 12 experts in the fields of interventional radiology and hepatology, convened by the Research Committee of the Korean Liver Cancer Association (KLCA), has developed expert consensus-based practical recommendations in TACE. These recommendations have been endorsed by the Korean Society of Interventional Radiology and provide useful information and direction in performing TACE procedure as well as pre- and post- procedural patient care.","PeriodicalId":16226,"journal":{"name":"Journal of Liver Cancer","volume":" ","pages":"241-261"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/2e/a3/jlc-2023-05-22.PMC10565548.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9779048","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical outcome of surgical resection for multifocal T2-T3 hepatocellular carcinoma up to 3 nodules: a comparative analysis with a single nodule. 多灶性T2-T3肝细胞癌手术切除3个结节的临床结果：与单个结节的比较分析。

Journal of Liver Cancer Pub Date : 2023-09-01 Epub Date: 2023-09-15 DOI: 10.17998/jlc.2023.08.24

Sehyeon Yu, Hye-Sung Jo, Young-Dong Yu, Yoo Jin Choi, Dong-Sik Kim

{"title":"Clinical outcome of surgical resection for multifocal T2-T3 hepatocellular carcinoma up to 3 nodules: a comparative analysis with a single nodule.","authors":"Sehyeon Yu, Hye-Sung Jo, Young-Dong Yu, Yoo Jin Choi, Dong-Sik Kim","doi":"10.17998/jlc.2023.08.24","DOIUrl":"10.17998/jlc.2023.08.24","url":null,"abstract":"Background/aims: Although the Barcelona Clinic Liver Cancer staging system seems to underestimate the impact of curative-intent surgical resection for multifocal hepatocellular carcinoma (HCC), recent studies have indicated favorable results for the surgical resection of multiple HCC. This study aimed to assess clinical outcomes and feasibility of surgical resection for multifocal HCC with up to three nodules compared with single tumor cases.Methods: Patients who underwent surgical resection for HCC with up to three nodules between 2009 and 2020 were included, and those with the American Joint Committee on Cancer (AJCC) 8th edition, T1 and T4 stages were excluded to reduce differences in disease distribution and severity. Finally, 81 and 52 patients were included in the single and multiple treatment groups, respectively. Short- and long-term outcomes including recurrence-free survival (RFS) and overall survival (OS), were evaluated.Results: All patients were classified as Child-Pugh class A. RFS and OS were not significantly different between the two groups (P=0.176 and P=0.966, respectively). Multivariate analysis revealed that transfusion and intrahepatic metastasis were significantly associated with recurrence (P=0.046 and P=0.005, respectively). Additionally, intrahepatic metastasis was significantly associated with OS (hazard ratio, 1.989; 95% confidence interval, 1.040-3.802; P=0.038).Conclusions: Since there was no significant difference in survival between the single and multiple groups among patients with AJCC 8th stage T2 and T3, surgical resection with curative intent could be considered with acceptable long-term survival for selected patients with multiple HCC of up to three nodules.","PeriodicalId":16226,"journal":{"name":"Journal of Liver Cancer","volume":" ","pages":"377-388"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/00/dc/jlc-2023-08-24.PMC10565552.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10288831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The efficacy of treatment for hepatocellular carcinoma in elderly patients. 老年人肝细胞癌的治疗效果。

Journal of Liver Cancer Pub Date : 2023-09-01 Epub Date: 2023-09-14 DOI: 10.17998/jlc.2023.08.03

Han Ah Lee, Sangheun Lee, Hae Lim Lee, Jeong Eun Song, Dong Hyeon Lee, Sojung Han, Ju Hyun Shim, Bo Hyun Kim, Jong Young Choi, Hyunchul Rhim, Do Young Kim

{"title":"The efficacy of treatment for hepatocellular carcinoma in elderly patients.","authors":"Han Ah Lee, Sangheun Lee, Hae Lim Lee, Jeong Eun Song, Dong Hyeon Lee, Sojung Han, Ju Hyun Shim, Bo Hyun Kim, Jong Young Choi, Hyunchul Rhim, Do Young Kim","doi":"10.17998/jlc.2023.08.03","DOIUrl":"10.17998/jlc.2023.08.03","url":null,"abstract":"Background/aim: Despite the increasing proportion of elderly patients with hepatocellular carcinoma (HCC) over time, treatment efficacy in this population is not well established.Methods: Data collected from the Korean Primary Liver Cancer Registry, a representative cohort of patients newly diagnosed with HCC in Korea between 2008 and 2017, were analyzed. Overall survival (OS) according to tumor stage and treatment modality was compared between elderly and non-elderly patients with HCC.Results: Among 15,186 study patients, 5,829 (38.4%) were elderly. A larger proportion of elderly patients did not receive any treatment for HCC than non-elderly patients (25.2% vs. 16.7%). However, OS was significantly better in elderly patients who received treatment compared to those who did not (median, 38.6 vs. 22.3 months; P<0.001). In early-stage HCC, surgery yielded significantly lower OS in elderly patients compared to non-elderly patients (median, 97.4 vs. 138.0 months; P<0.001), however, local ablation (median, 82.2 vs. 105.5 months) and transarterial therapy (median, 42.6 vs. 56.9 months) each provided comparable OS between the two groups after inverse probability of treatment weighting (IPTW) analysis (all P>0.05). After IPTW, in intermediate-stage HCC, surgery (median, 66.0 vs. 90.3 months) and transarterial therapy (median, 36.5 vs. 37.2 months), and in advanced-stage HCC, transarterial (median, 25.3 vs. 26.3 months) and systemic therapy (median, 25.3 vs. 26.3 months) yielded comparable OS between the elderly and non-elderly HCC patients (all P>0.05).Conclusions: Personalized treatments tailored to individual patients can improve the prognosis of elderly patients with HCC to a level comparable to that of non-elderly patients.","PeriodicalId":16226,"journal":{"name":"Journal of Liver Cancer","volume":" ","pages":"362-376"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/3f/d6/jlc-2023-08-03.PMC10565541.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10222867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Diagnosis of hepatocellular carcinoma using Sonazoid: a comprehensive review. Sonazoid对肝细胞癌的诊断：综述。

Journal of Liver Cancer Pub Date : 2023-09-01 Epub Date: 2023-09-19 DOI: 10.17998/jlc.2023.08.25

Woo Kyoung Jeong

{"title":"Diagnosis of hepatocellular carcinoma using Sonazoid: a comprehensive review.","authors":"Woo Kyoung Jeong","doi":"10.17998/jlc.2023.08.25","DOIUrl":"10.17998/jlc.2023.08.25","url":null,"abstract":"Sonazoid contrast-enhanced ultrasonography (CEUS) is a promising technique for the detection and diagnosis of focal liver lesions, particularly hepatocellular carcinoma (HCC). Recently, a collaborative effort between the Korean Society of Radiology and Korean Society of Abdominal Radiology resulted in the publication of guidelines for diagnosing HCC using Sonazoid CEUS. These guidelines propose specific criteria for identifying HCC based on the imaging characteristics observed during Sonazoid CEUS. The suggested diagnostic criteria include nonrim arterial phase hyperenhancement, and the presence of late and mild washout, or Kupffer phase washout under the premise that the early or marked washout should not occur during the portal venous phase. These criteria aim to improve the accuracy of HCC diagnosis using Sonazoid CEUS. This review offers a comprehensive overview of Sonazoid CEUS in the context of HCC diagnosis. It covers the fundamental principles of Sonazoid CEUS and its clinical applications, and introduces the recently published guidelines. By providing a summary of this emerging technique, this review contributes to a better understanding of the potential role of Sonazoid CEUS for diagnosing HCC.","PeriodicalId":16226,"journal":{"name":"Journal of Liver Cancer","volume":" ","pages":"272-283"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/fb/31/jlc-2023-08-25.PMC10565540.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10302042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A single hepatic mass with two tales: hepatic tuberculosis and hepatocellular carcinoma. 一个单一的肝脏肿块，有两个故事：肝结核和肝细胞癌。

Journal of Liver Cancer Pub Date : 2023-09-01 Epub Date: 2023-09-08 DOI: 10.17998/jlc.2023.08.30

Yi De Ian Koh, Wei-Qiang Leow

引用次数: 0

The role of lenvatinib in the era of immunotherapy of hepatocellular carcinoma. 乐伐替尼在肝细胞癌免疫治疗时代的作用。

Journal of Liver Cancer Pub Date : 2023-09-01 Epub Date: 2023-08-17 DOI: 10.17998/jlc.2023.07.17

Matthew Man Pok Lee, Landon Long Chan, Stephen Lam Chan

{"title":"The role of lenvatinib in the era of immunotherapy of hepatocellular carcinoma.","authors":"Matthew Man Pok Lee, Landon Long Chan, Stephen Lam Chan","doi":"10.17998/jlc.2023.07.17","DOIUrl":"10.17998/jlc.2023.07.17","url":null,"abstract":"Hepatocellular carcinoma (HCC) frequently presents as advanced stage with poor prognosis and high mortality. Systemic treatment is the treatment of choice for advanced disease. In 2007, the first multi-kinase inhibitor (MKI) sorafenib was approved and shown to modestly prolong overall survival (OS). The progress of systemic therapy has been slow afterwards until 2018 when lenvatinib, another MKI, was shown to be non-inferior to sorafenib on median OS as the first-line therapy for HCC. Since then, remarkable progress has been achieved on the treatment of advanced HCC, including the development of second-line targeted treatment, including regorafenib, cabozantinib and ramucirumab from 2017 to 2019. A growing focus has been placed on immune checkpoint inhibitors (ICIs) targeting programmed cell death-1 (PD-1), its ligand PD-L1, and cytotoxic T-lymphocyte-associated protein 4. These ICIs have proven their potency in treating HCC as both initial and subsequent line of therapy. At present, both regimens of atezolizumab combined with bevacizumab, as well as the combination of tremelimumab and durvalumab, are recommended as the first-line treatments based on positive phase III clinical trials. With the advancement of ICIs, it is anticipated that the role of MKIs in the treatment of HCC will evolve. In this article, lenvatinib, one of the most commonly used MKIs in HCC, is chosen to be reviewed.","PeriodicalId":16226,"journal":{"name":"Journal of Liver Cancer","volume":" ","pages":"262-271"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/fd/11/jlc-2023-07-17.PMC10565543.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10389840","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Isolation and characterization of cancer-associated fibroblasts in the tumor microenvironment of hepatocellular carcinoma. 肝细胞癌肿瘤微环境中癌相关成纤维细胞的分离与鉴定。

Journal of Liver Cancer Pub Date : 2023-09-01 Epub Date: 2023-06-12 DOI: 10.17998/jlc.2023.04.30

Kyoungdo Mun, Jiwon Han, Pureun Roh, Jonggeun Park, Gahee Kim, Wonhee Hur, Jeongwon Jang, Jongyoung Choi, Seungkew Yoon, Youngkyoung You, Hojoong Choi, Pilsoo Sung

{"title":"Isolation and characterization of cancer-associated fibroblasts in the tumor microenvironment of hepatocellular carcinoma.","authors":"Kyoungdo Mun, Jiwon Han, Pureun Roh, Jonggeun Park, Gahee Kim, Wonhee Hur, Jeongwon Jang, Jongyoung Choi, Seungkew Yoon, Youngkyoung You, Hojoong Choi, Pilsoo Sung","doi":"10.17998/jlc.2023.04.30","DOIUrl":"10.17998/jlc.2023.04.30","url":null,"abstract":"Background/aim: Cancer-associated fibroblasts (CAFs) play an immunosuppressive role in the tumor microenvironment (TME) of human cancers; however, their characteristics and role in hepatocellular carcinoma (HCC) remain to be elucidated.Methods: Nine tumor and surrounding liver tissue samples from patients with HCC who underwent surgery were used to isolate patient-derived CAFs. Cell morphology was observed using an optical microscope after culture, and cell phenotypes were evaluated using flow cytometry and immunoblotting. Cytokines secreted by CAFs into culture medium were quantified using a multiplex cytokine assay.Results: CAFs were abundant in the TME of HCC and were adjacent to immune cells. After culture, the CAFs and non-tumor fibroblasts exhibited spindle shapes. We observed a robust expression of alpha-smooth muscle actin and fibroblast activation protein in CAFs, whereas alpha-fetoprotein, epithelial cell adhesion molecule, platelet/endothelial cell adhesion molecule-1, and E-cadherin were not expressed in CAFs. Furthermore, CAFs showed high secretion of various cytokines, namely C-X-C motif chemokine ligand 12, interleukin (IL)-6, IL-8, and C-C motif chemokine ligand 2.Conclusions: CAFs are abundant in the TME of HCC and play a crucial role in tumor progression. These fibroblasts secrete cytokines that promote tumor growth and metastasis.","PeriodicalId":16226,"journal":{"name":"Journal of Liver Cancer","volume":" ","pages":"341-349"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/55/05/jlc-2023-04-30.PMC10565539.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10242608","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Implications of the first edition of the Korean expert consensus-based practice recommendations for transarterial chemoembolization in the management of hepatocellular carcinoma. 第一版韩国专家基于共识的实践建议对肝细胞癌经动脉化疗栓塞治疗的影响。

Journal of Liver Cancer Pub Date : 2023-09-01 Epub Date: 2023-07-25 DOI: 10.17998/jlc.2023.06.29

Jin Wook Chung

引用次数: 0

Hepatic basidiobolomycosis masquerading as cholangiocarcinoma: a case report and literature review. 伪装成胆管癌的肝脏担担菌病：一例报告和文献复习。

Journal of Liver Cancer Pub Date : 2023-09-01 Epub Date: 2023-08-17 DOI: 10.17998/jlc.2023.06.07

Roopali Sehrawat, Nalini Bansal, Ajitabh Srivastava, Dharmender Malik, Vivek Vij

引用次数: 0

Imaging prognostication and tumor biology in hepatocellular carcinoma. 肝细胞癌的影像学预测和肿瘤生物学。

Journal of Liver Cancer Pub Date : 2023-09-01 Epub Date: 2023-09-15 DOI: 10.17998/jlc.2023.08.29

Diana Kadi, Marilyn F Yamamoto, Emily C Lerner, Hanyu Jiang, Kathryn J Fowler, Mustafa R Bashir

引用次数: 0